Cargando…

Assessment of Loiasis and Outcomes of Ivermectin Masstreatment in Ijebu-North, Nigeria

A total of 286 individuals from 3 selected communities (Areedi-Aje, Ipakodo/Ojokodo, and Ijebu-Igbo) of Ijebu-North, southwestern Nigeria were examined for Loa loa microfilaremia using finger prick blood smear, between December 2008 and March 2009. Rapid assessment procedure for loiasis (RAPLOA) was...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, A. A., Akinsanya, B., Iyase, N., Owagboriaye, F. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Parasitology 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121072/
https://www.ncbi.nlm.nih.gov/pubmed/21738271
http://dx.doi.org/10.3347/kjp.2011.49.2.153
_version_ 1782206792545075200
author Hassan, A. A.
Akinsanya, B.
Iyase, N.
Owagboriaye, F. O.
author_facet Hassan, A. A.
Akinsanya, B.
Iyase, N.
Owagboriaye, F. O.
author_sort Hassan, A. A.
collection PubMed
description A total of 286 individuals from 3 selected communities (Areedi-Aje, Ipakodo/Ojokodo, and Ijebu-Igbo) of Ijebu-North, southwestern Nigeria were examined for Loa loa microfilaremia using finger prick blood smear, between December 2008 and March 2009. Rapid assessment procedure for loiasis (RAPLOA) was used to obtain information, from 187 Ijebu-Igbo residents, on adverse reactions experienced from retrospective treatments with ivermectin and history of eye worm. Only 33.9% of the respondents reported having had a history of eye worm while 33.2% had microfilaremia. The demographic factor of gender was not significant determinants of the prevalence (P>0.05) while age was significant (P<0.05). The highest prevalence of eye worm history and microfilaremia were recorded in 61-70 and 15-20 years of age categories, respectively. Ijebu-Igbo had 27.3% eye worm history, 32.1% microfilaremia, and the highest intensity of 140 microfilariae (mf)/ml. Ipakodo area had the highest eye worm history of 54.4% and the highest intensity of 420 mf/ml. Areedi-Aje had the highest occurrence of 45.2% microfilaremia and the highest intensity of 460 mf/ml. Predictably, Areedi-Aje and Ipakodo areas were high risk communities. The low intensity of L. loa infection with an insignificant (2.1%; P>0.05) adverse reactions from 187 subjects involved in the retrospective ivermectin administration confirmed that ivermectin delivery may be considered safe. The community-directed treatment with ivermectin (CDTI) programme was most probably responsible for the low prevalence and intensity.
format Online
Article
Text
id pubmed-3121072
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The Korean Society for Parasitology
record_format MEDLINE/PubMed
spelling pubmed-31210722011-07-07 Assessment of Loiasis and Outcomes of Ivermectin Masstreatment in Ijebu-North, Nigeria Hassan, A. A. Akinsanya, B. Iyase, N. Owagboriaye, F. O. Korean J Parasitol Original Article A total of 286 individuals from 3 selected communities (Areedi-Aje, Ipakodo/Ojokodo, and Ijebu-Igbo) of Ijebu-North, southwestern Nigeria were examined for Loa loa microfilaremia using finger prick blood smear, between December 2008 and March 2009. Rapid assessment procedure for loiasis (RAPLOA) was used to obtain information, from 187 Ijebu-Igbo residents, on adverse reactions experienced from retrospective treatments with ivermectin and history of eye worm. Only 33.9% of the respondents reported having had a history of eye worm while 33.2% had microfilaremia. The demographic factor of gender was not significant determinants of the prevalence (P>0.05) while age was significant (P<0.05). The highest prevalence of eye worm history and microfilaremia were recorded in 61-70 and 15-20 years of age categories, respectively. Ijebu-Igbo had 27.3% eye worm history, 32.1% microfilaremia, and the highest intensity of 140 microfilariae (mf)/ml. Ipakodo area had the highest eye worm history of 54.4% and the highest intensity of 420 mf/ml. Areedi-Aje had the highest occurrence of 45.2% microfilaremia and the highest intensity of 460 mf/ml. Predictably, Areedi-Aje and Ipakodo areas were high risk communities. The low intensity of L. loa infection with an insignificant (2.1%; P>0.05) adverse reactions from 187 subjects involved in the retrospective ivermectin administration confirmed that ivermectin delivery may be considered safe. The community-directed treatment with ivermectin (CDTI) programme was most probably responsible for the low prevalence and intensity. The Korean Society for Parasitology 2011-06 2011-06-14 /pmc/articles/PMC3121072/ /pubmed/21738271 http://dx.doi.org/10.3347/kjp.2011.49.2.153 Text en © 2011, Korean Society for Parasitology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hassan, A. A.
Akinsanya, B.
Iyase, N.
Owagboriaye, F. O.
Assessment of Loiasis and Outcomes of Ivermectin Masstreatment in Ijebu-North, Nigeria
title Assessment of Loiasis and Outcomes of Ivermectin Masstreatment in Ijebu-North, Nigeria
title_full Assessment of Loiasis and Outcomes of Ivermectin Masstreatment in Ijebu-North, Nigeria
title_fullStr Assessment of Loiasis and Outcomes of Ivermectin Masstreatment in Ijebu-North, Nigeria
title_full_unstemmed Assessment of Loiasis and Outcomes of Ivermectin Masstreatment in Ijebu-North, Nigeria
title_short Assessment of Loiasis and Outcomes of Ivermectin Masstreatment in Ijebu-North, Nigeria
title_sort assessment of loiasis and outcomes of ivermectin masstreatment in ijebu-north, nigeria
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121072/
https://www.ncbi.nlm.nih.gov/pubmed/21738271
http://dx.doi.org/10.3347/kjp.2011.49.2.153
work_keys_str_mv AT hassanaa assessmentofloiasisandoutcomesofivermectinmasstreatmentinijebunorthnigeria
AT akinsanyab assessmentofloiasisandoutcomesofivermectinmasstreatmentinijebunorthnigeria
AT iyasen assessmentofloiasisandoutcomesofivermectinmasstreatmentinijebunorthnigeria
AT owagboriayefo assessmentofloiasisandoutcomesofivermectinmasstreatmentinijebunorthnigeria